TAK1 drives inflammatory fibroblast acquisition and shapes myocardial infarction responses in male mice Authors: Daniel C. Nguyen, Jonah K. Stephan, Lianay Gutierrez Luque, Robert E. Brainard, Kenneth R. Brittian, Collin K. Wells, Madison S. Teer, Yania Martinez-Ondaro, Kara R. Gouwens, Danielle T. Little, Yibing Nong, Nolan L. Boyd, Ashok Kumar, Steven P. Jones, Richa Singhal, Jason Hellmann, Marcin Wysoczynski, Bradford G. Hill Published: 2026 ABSTRACT Organ function depends on communication among cell types to coordinate tissue growth and repair. Although fibroblasts are critical to this process, their role in regulating inflammatory responses to injury remain ambiguous. Here, we show that transforming growth factor β-activated kinase 1 (TAK1) is a gatekeeper of an inflammatory cardiac fibroblast phenotype. In cardiac fibroblasts, TAK1 signaling controls the acquisition of defining features of inflammatory fibroblasts, including chemokine and cytokine synthesis, lipid mediator production, metalloproteinase activity, and damage-associated molecular pattern recognition. Moreover, TAK1 propagates IL-1β and TNF-α signaling, but not TGF-β-SMAD signaling, regulating inflammatory programs by increasing chemokine secretion while decreasing lipid mediator production. Fibroblast-specific TAK1 deletion decreases neutrophil chemotaxis in vitro and immune cell recruitment after myocardial infarction in vivo, which is associated with improved cardiac remodeling and function in male mice. These results further resolve the nature and function of inflammatory fibroblasts in cardiac responses to injury and identify TAK1 signaling as a critical mediator. Introduction Inflammation is a highly coordinated response to tissue infection or injury that is essential for repair, yet when excessive or unresolved, contributes to fibrosis and organ dysfunction. This duality is particularly evident after myocardial infarction (MI), where a rapid inflammatory response is required to limit injury, clear necrotic tissue, and initiate replacement fibrosis1, but persistent low-grade inflammation promotes adverse myocardial remodeling and increases cardiovascular disease risk1,2. Recent studies indicate that inflammatory cues from myeloid cells to cardiac fibroblasts are critical determinants of post-infarct remodeling, with blockade of interleukin 1 (IL-1) signaling attenuating fibrosis and heart failure in preclinical models3,4 and having promising effects on cardiovascular endpoints and heart failure in humans5. Despite these advances, the mechanisms by which inflammatory signals are interpreted by fibroblasts to shape repair versus maladaptive remodeling remain poorly defined. Following MI, fibroblasts undergo a transition to an inflammatory phenotype that is transcriptionally and functionally distinct from myofibroblasts6. These inflammatory fibroblasts are proposed to regulate paracrine and autocrine signaling, coordinate immune cell recruitment and activation, and influence the trajectory of post-infarct remodeling7,8. However, how fibroblasts acquire this inflammatory state, and how inflammatory signaling is selectively integrated to produce coordinated immune-modulatory outputs, remain unresolved questions. Among the pathways that could propagate inflammatory and profibrotic signaling, transforming growth factor-β-activated kinase 1 (TAK1) is a conspicuous candidate. Although originally identified as a mediator of TGF-β signaling9, TAK1 is now recognized as a convergence point for IL-1 receptors, toll-like receptors, and tumor necrosis factor receptors, activating downstream inflammatory pathways including NF-κB, JNK, and p38 MAPK10,11. Although TAK1 has been implicated in inflammatory signaling across multiple cell types, its role in regulating fibroblast inflammatory state transitions and fibroblast-mediated cardiac repair has not been defined. Here, we investigated whether TAK1 functions as a determinant of inflammatory fibroblast differentiation and post-MI remodeling. We show that TAK1 selectively governs acquisition of an inflammatory cardiac fibroblast phenotype, coordinating chemokine and cytokine production, lipid mediator metabolism, immune cell recruitment, and myocardial remodeling after MI. These findings identify TAK1 as a critical signaling node that enables fibroblasts to integrate inflammatory cues and actively shape inflammatory and reparative responses following cardiac injury. Results Inflammatory fibroblasts appear early after MI To characterize the inflammatory cardiac fibroblasts that emerge following myocardial injury, we analyzed fibroblast subclusters from a snRNA-seq dataset12 obtained at 0, 1, 4, 7, and 28 days after non-reperfused MI in male and female mice. Fibroblast-enriched clusters (1, 4, 14, and 18) were selected for subclustering based on co-expression of canonical fibroblast markers such as Col1a1, Col1a2, and Pdgfra (Fig. 1a). This analysis identified five transcriptionally distinct fibroblast populations: quiescent fibroblasts, inflammatory fibroblasts, myofibroblasts, matrifibrocytes, and epicardial fibroblasts (Fig. 1b).Fig. 1Time-resolved transcriptional responses of fibroblast subclusters after myocardial infarction in male and female mice.Single-nucleus RNA-seq data were collected at days 0 (baseline), 1, 4, 7, and 28 post-MI. a Feature plot showing co-expression of fibroblast markers Col1a1, Col1a2, and Pdgfra across all cardiac cell types. Color intensity reflects SCTransform-normalized expression (gray–blue). b UMAP visualization of fibroblast-enriched clusters (clusters 1, 4, 14, and 18) illustrates unsupervised sub-clustering, identifying five cardiac fibroblast subtypes. c UMAP plots depicting temporal transitions in fibroblast subcluster populations across post-MI time points in female (top panel) and male (bottom panel) mice. d Corresponding stacked bar plots show the proportional distribution of fibroblast subclusters across the same time points. e Bubble plot showing differential expression of inflammatory genes within the inflammatory fibroblast subcluster in female and male hearts at days 1, 4, 7, and 28 post-MI. Differentially expressed genes were identified using Seurat’s FindMarkers. Bubble size represents log₂ fold change; bubble color reflects direction and significance (dark red = significant downregulation, light red = non-significant downregulation; dark blue = significant upregulation, light blue = non-significant upregulation). f Feature plots showing expression of Ccl2, Il6, and Ptgs2 across fibroblast subclusters, with SCTransform-normalized expression represented from low (gray) to high (blue). Source data are from GSE308914. Time-resolved transcriptional responses of fibroblast subclusters after myocardial infarction in male and female mice. Single-nucleus RNA-seq data were collected at days 0 (baseline), 1, 4, 7, and 28 post-MI. a Feature plot showing co-expression of fibroblast markers Col1a1, Col1a2, and Pdgfra across all cardiac cell types. Color intensity reflects SCTransform-normalized expression (gray–blue). b UMAP visualization of fibroblast-enriched clusters (clusters 1, 4, 14, and 18) illustrates unsupervised sub-clustering, identifying five cardiac fibroblast subtypes. c UMAP plots depicting temporal transitions in fibroblast subcluster populations across post-MI time points in female (top panel) and male (bottom panel) mice. d Corresponding stacked bar plots show the proportional distribution of fibroblast subclusters across the same time points. e Bubble plot showing differential expression of inflammatory genes within the inflammatory fibroblast subcluster in female and male hearts at days 1, 4, 7, and 28 post-MI. Differentially expressed genes were identified using Seurat’s FindMarkers. Bubble size represents log₂ fold change; bubble color reflects direction and significance (dark red = significant downregulation, light red = non-significant downregulation; dark blue = significant upregulation, light blue = non-significant upregulation). f Feature plots showing expression of Ccl2, Il6, and Ptgs2 across fibroblast subclusters, with SCTransform-normalized expression represented from low (gray) to high (blue). Source data are from GSE308914. We next examined how the abundance of each fibroblast population changed after MI. Prior to MI, inflammatory fibroblasts comprised approximately 5% of the fibroblast population. By 1-day post-MI, they expanded to ~30% of all cardiac fibroblasts, before declining to ~10% by day 4 and remaining at low levels at days 7 and 28 (Fig. 1c, d). In contrast, myofibroblasts expanded later, peaking between days 4–7 post-MI and accounting for 50–60% of the fibroblast population. By day 28, myofibroblasts diminished and were accompanied by the emergence of a substantial matrifibrocyte population13 comprising 25–30% of fibroblast population (Fig. 1c, d). Epicardial fibroblasts remained a minor population with relatively stable representation throughout the post-MI time course. These data indicate that inflammatory fibroblasts represent an early, transient fibroblast state that temporally precedes myofibroblast accumulation. To define the functional characteristics of inflammatory fibroblasts, we assessed expression of genes associated with inflammatory signaling, immune cell recruitment, and lipid mediator synthesis within this population. Inflammatory fibroblasts from both male and female hearts exhibited elevated transcript levels for chemokines and cytokines involved in immune cell recruitment and activation (e.g., Ccl2, Cxcl1, Il6, Saa3), matrix remodeling enzymes (e.g., Mmp3), and lipid mediator synthesis enzymes (e.g., Ptgs2, Ptges3, Pla2g4a) at early timepoints post-MI when compared to day 0 (Fig. 1e). UMAP feature plots demonstrated that the inflammatory fibroblast subcluster exhibited elevated expression of key inflammatory and lipid mediator-associated genes, including Ccl2, Il6, and Ptgs2, after MI (Fig. 1f). Notably, many of these genes are canonical targets of NF-κB and stress-kinase pathways, including p38 and JNK. Consistent with this, pathway-focused analysis revealed a marked increase in differentially expressed NF-κB- and stress kinase-associated transcripts at days 1 and 4 post-MI, followed by a progressive decline thereafter (Supplementary Fig. 1). Together, these findings identify a temporally restricted inflammatory population that emerges early after MI and is characterized by coordinated activation of inflammatory and stress-responsive transcriptional programs. Fibroblast TAK1 regulates inflammatory signaling and protein secretion Recent studies identified ligands such as IL-1β and TGF-β to be among the strongest signals received by fibroblasts after MI3,4. In the context of cardiovascular diseases, IL-1β and its associated signaling responses are of interest, given the potential efficacy of IL-1β blockade (reviewed in ref. 14). Moreover, other ligands involved in inflammation and cardiac repair, such as TNF-α and TGF-β, respectively, are also elevated after MI and play important roles in myocardial remodeling and fibrosis1. Collectively, these ligands can trigger inflammatory (NF-κB), stress kinase (p38, JNK), or Smad pathway activation (Fig. 2a). Because IL-1β, TNF-α, and TGF-β activate distinct receptor-proximal signaling cascades, we reasoned that comparing their effects in cardiac fibroblasts would help identify signaling pathways selectively engaged during inflammatory versus fibrotic activation. Treatment with IL-1β or TNF-α caused rapid (within 15 min) and robust activation of the NF-κB pathway, as exemplified by increased p-NF-κB abundance and IκBα degradation. Moreover, IL-1β treatment activated both SAPK/JNK and p38 to a greater extent than the other tested ligands (Fig. 2b).Fig. 2IL-1β activates pro-inflammatory signaling and enhances protein synthesis and secretion in cardiac fibroblasts without promoting myofibroblast differentiation.a Schematic illustrating TAK1-dependent signaling pathways downstream of inflammatory and fibrogenic ligands. b Representative immunoblots showing activation of inflammatory and stress kinase signaling pathways in isolated adult cardiac fibroblasts stimulated with indicated ligands for up to 120 min. n = 1 independent biological replicate per group. c–f Representative immunoblots (c) and densitometric quantification (d–f) of collagen (Col1), periostin, and α-smooth muscle actin (α-SMA) in fibroblasts following 48 h of ligand stimulation. g–j Conditioned medium from fibroblasts treated with ligands for up to 48 h and pulsed with puromycin for 30 min was analyzed by immunoblot (g) and quantified for secreted puromycin-labeled proteins (h), collagen (i), and periostin (j). Data are mean ± SEM. Proteins were normalized to amido black signal from stained membranes (d–f) or total cellular protein (h–j). Experiments and blots were processed in parallel and normalized to an anchor protein. n = 4 biological replicates per group. Statistical procedures: (d–f) ordinary one-way ANOVA with Dunnett post-hoc test; (h–j) two-way ANOVA with Šidák’s post-hoc test. h p < 0.0001 IL-1β vs bFGF, p < 0.0001 IL-1β vs TGFβ, i p < 0.0001 TGFβ vs bFGF, p < 0.0001 IL-1β vs TGFβ, j p = 0.0011 IL-1β vs bFGF, p < 0.0001 TGFβ vs bFGF. Schematic in a was created in BioRender. Nguyen, D. (https://BioRender.com/p7z9ro6). Source data are provided as a Source Data file. IL-1β activates pro-inflammatory signaling and enhances protein synthesis and secretion in cardiac fibroblasts without promoting myofibroblast differentiation. a Schematic illustrating TAK1-dependent signaling pathways downstream of inflammatory and fibrogenic ligands. b Representative immunoblots showing activation of inflammatory and stress kinase signaling pathways in isolated adult cardiac fibroblasts stimulated with indicated ligands for up to 120 min. n = 1 independent biological replicate per group. c–f Representative immunoblots (c) and densitometric quantification (d–f) of collagen (Col1), periostin, and α-smooth muscle actin (α-SMA) in fibroblasts following 48 h of ligand stimulation. g–j Conditioned medium from fibroblasts treated with ligands for up to 48 h and pulsed with puromycin for 30 min was analyzed by immunoblot (g) and quantified for secreted puromycin-labeled proteins (h), collagen (i), and periostin (j). Data are mean ± SEM. Proteins were normalized to amido black signal from stained membranes (d–f) or total cellular protein (h–j). Experiments and blots were processed in parallel and normalized to an anchor protein. n = 4 biological replicates per group. Statistical procedures: (d–f) ordinary one-way ANOVA with Dunnett post-hoc test; (h–j) two-way ANOVA with Šidák’s post-hoc test. h p < 0.0001 IL-1β vs bFGF, p < 0.0001 IL-1β vs TGFβ, i p < 0.0001 TGFβ vs bFGF, p < 0.0001 IL-1β vs TGFβ, j p = 0.0011 IL-1β vs bFGF, p < 0.0001 TGFβ vs bFGF. Schematic in a was created in BioRender. Nguyen, D. (https://BioRender.com/p7z9ro6). Source data are provided as a Source Data file. We next tested the effects of each ligand on classical myofibroblast activation markers. Notably, IL-1β attenuates TGF-β-induced myofibroblast differentiation while also regulating the synthesis and secretion of cytokines and chemokines8. Indeed, we found that IL-1β attenuated TGF-β-induced periostin and α-smooth muscle actin (α-SMA) abundance but did not affect TGF-β-stimulated collagen upregulation (Fig. 2c–f). To determine whether IL-1β influences protein synthesis and secretion, we leveraged the SUnSET assay15 to measure the secretion and relative abundance of newly synthesized proteins in the culture medium. Cardiac fibroblasts were serum-starved (control) or treated with basic fibroblast growth factor (bFGF), TGF-β, or IL-1β for up to 48 h, followed by a 30 min pulse of low-dose puromycin—a structural analog of tyrosyl-tRNA that is incorporated into elongating peptide chains. More than any other tested ligand, medium from IL-1β-treated cells showed markedly higher levels of puromycin-labeled proteins, indicating that IL-1β drives a highly secretory fibroblast phenotype characterized by rapid protein synthesis and secretion (Fig. 2g, h). Although both IL-1β and TGF-β promoted secretion of collagen into the medium (Fig. 2g, j), only TGF-β increased periostin (Fig. 2g, i), insinuating that the puromycin-labeled proteins from IL-1β-stimulated fibroblasts likely consist of proteins other than fundamental components of the extracellular matrix. We next determined the extent to which proinflammatory and fibrotic signaling is propagated through TAK1, which is a signaling nexus with cell type-specific functions10. To determine the role of TAK1 in regulating inflammatory signaling in cardiac fibroblasts, we used a murine TAK1fl/fl model, which possesses loxP sites flanking Exon 2 of the TAK1 (Map3k7) gene16 (Fig. 3a). Exon 2 encodes the ATP-binding site, necessary for TAK1 phosphorylation and activation. Hence, Cre-mediated recombination in TAK1fl/fl cardiac fibroblasts should lead to a truncated TAK1 product (TAK1Δ) with abolished kinase activity. Indeed, adenoviral expression of Cre recombinase (Ad-CMV-iCre) in TAK1fl/fl cardiac fibroblasts led to the appearance of TAK1Δ within 3 d of transduction (Fig. 3b); culture for 4 additional days led to disappearance of the TAK1Δ product, suggesting that TAK1Δ is ultimately degraded (Fig. 3c). Notably, TAK1 deletion did not affect cell number, suggesting that it likely does not influence cell proliferation or viability in unstimulated cells (Fig. 3d). Genetic deletion of TAK1 abolished both TNF-α- and IL-1β-mediated activation of the NF-κB, p38, and SAPK/JNK signaling pathways (Fig. 3e–h); however, TAK1 deletion did not affect TGF-β-induced activation of SMAD3 or p38 (Fig. 3i, j). Notably, we found that female cardiac fibroblasts responded to IL-1β in an identical manner to male fibroblasts (Supplementary Fig. 2). Collectively, these data suggest that, in cardiac fibroblasts, TAK1 propagates inflammatory, but not SMAD, signaling.Fig. 3TAK1 propagates inflammatory signaling in cardiac fibroblasts.a Schematic of TAK1 conditional allele with LoxP sites flanking exon 2. Cre recombination yields a truncated TAK1 product. b, c Validation of Cre-mediated TAK1 truncation (TAK1Δ) in isolated TAK1fl/fl cardiac fibroblasts 3 (b) and 7 (c) days after adenovirus (Ad-CMV-iCre) treatment. d Proliferation and viability of isolated cardiac TAK1fl/fl fibroblasts transduced with LacZ or iCre were assessed for up to 4 days using PrestoBlue assay. n = 4 independent biological replicates per group. e–j Representative immunoblots and densitometry of inflammatory and stress signaling proteins in control (Ad-CMV-LacZ) or iCre-pretreated TAK1fl/fl cardiac fibroblasts. Fibroblasts were treated without or with TNF-α (e, f), IL-1β (g, h), or TGFβ (i, j) for 30 min prior to cell lysis and collection. n = 5 independent biological replicates per group. Data are mean ± SEM. Statistical procedures: two-way ANOVA with Šidák’s post-hoc. f TNFα_LacZ vs TNFα_iCre, p = 0.0167 pNFκB, p < 0.0001 p38, p < 0.0001 SAPK/JNK, p < 0.0001 IκBα. h IL-1β_LacZ vs IL-1β_iCre, p = 0.0160 pNFκB, p = 0.0072 p38, p < 0.0001 SAPK/JNK, p < 0.0001 IκBα. Experiments and blots were processed in parallel and normalized to an anchor protein. Schematic in (a) was Created in BioRender. Wells, C. (https://BioRender.com/owtrv1n). Source data are provided as a Source Data file. TAK1 propagates inflammatory signaling in cardiac fibroblasts. a Schematic of TAK1 conditional allele with LoxP sites flanking exon 2. Cre recombination yields a truncated TAK1 product. b, c Validation of Cre-mediated TAK1 truncation (TAK1Δ) in isolated TAK1fl/fl cardiac fibroblasts 3 (b) and 7 (c) days after adenovirus (Ad-CMV-iCre) treatment. d Proliferation and viability of isolated cardiac TAK1fl/fl fibroblasts transduced with LacZ or iCre were assessed for up to 4 days using PrestoBlue assay. n = 4 independent biological replicates per group. e–j Representative immunoblots and densitometry of inflammatory and stress signaling proteins in control (Ad-CMV-LacZ) or iCre-pretreated TAK1fl/fl cardiac fibroblasts. Fibroblasts were treated without or with TNF-α (e, f), IL-1β (g, h), or TGFβ (i, j) for 30 min prior to cell lysis and collection. n = 5 independent biological replicates per group. Data are mean ± SEM. Statistical procedures: two-way ANOVA with Šidák’s post-hoc. f TNFα_LacZ vs TNFα_iCre, p = 0.0167 pNFκB, p < 0.0001 p38, p < 0.0001 SAPK/JNK, p < 0.0001 IκBα. h IL-1β_LacZ vs IL-1β_iCre, p = 0.0160 pNFκB, p = 0.0072 p38, p < 0.0001 SAPK/JNK, p < 0.0001 IκBα. Experiments and blots were processed in parallel and normalized to an anchor protein. Schematic in (a) was Created in BioRender. Wells, C. (https://BioRender.com/owtrv1n). Source data are provided as a Source Data file. Fibroblast TAK1 influences cardiac remodeling after MI To delineate the in vivo role of fibroblast TAK1 signaling in the heart, we generated mice with tamoxifen-inducible, fibroblast-specific deletion of TAK1 by crossing TAK1fl/fl mice with Col1a2-CreERT mice. This Cre driver was selected because genetic fate-mapping studies demonstrate that Cre expression in these mice is largely restricted to fibroblasts, with Cre expression detected in cells expressing the fibroblast markers Vim and Ddr2, but not in endothelial cells or cardiomyocytes17. Efficient and sustained deletion of TAK1 in cardiac fibroblasts was confirmed by immunoblot analysis of cardiac fibroblasts isolated from tamoxifen-treated TAK1fl/fl (fbTAK1+) and TAK1fl/fl:Col1a2CreERT(fbTAK1–) mice (Supplementary Fig. 3a–c). Notably, fibroblast-specific TAK1 deletion had no effect on cardiac structure or function under unstressed conditions in either male or female mice for up to 16 weeks following tamoxifen administration, as assessed by echocardiography (Supplementary Tables 1 and 2). To assess the contextual specificity of fibroblast TAK1 signaling, we first examined its role in pressure overload-induced cardiac remodeling, a model driven predominantly by sustained mechanical stress with limited inflammatory activation compared with other heart failure models such as MI18,19. Following tamoxifen administration, fbTAK1+ and fbTAK1– mice were subjected to transverse aortic constriction (TAC), with serial echocardiographic assessments performed at baseline and at 4, 8, and 12 weeks post-surgery (Supplementary Fig. 3d). Gravimetric analyses revealed no differences in body mass or heart weight normalized to tibia length between genotypes 12 weeks post-TAC (Supplementary Fig. 3e; Supplementary Tables 3, 4). Consistent with progressive pressure overload-induced heart failure, both fbTAK1⁺ and fbTAK1⁻ mice exhibited ventricular dilation and declining ejection fraction over time, with no significant differences in cardiac structure or function between genotypes (Supplementary Tables 3, 4). Similarly, cardiac collagen content measured via hydroxyproline assay was comparable between fbTAK1+ and fbTAK1– hearts 12 weeks post-TAC (Supplementary Fig. 3f). Pressure-volume loop analyses performed in a subset of mice further confirmed the absence of genotype-dependent differences in indices of cardiac compliance (EDPVR) or contractility (ESPVR) (Supplementary Table 5). Collectively, these results suggest that fibroblast TAK1 signaling is dispensable for pathological remodeling driven by chronic pressure overload. In contrast to pressure overload, MI elicits a robust inflammatory response20, prompting us to examine whether fibroblast TAK1 contributes to cardiac remodeling after acute ischemic injury. Following tamoxifen administration and washout, fbTAK1⁺ and fbTAK1⁻ mice underwent permanent coronary artery ligation to induce non-reperfused MI (Fig. 4a). Efficient recombination was verified in a subset of animals by isolating cardiac fibroblasts and assessing TAK1 abundance. Although fibroblasts from female mice exhibited slightly higher baseline TAK1 expression than those from males, Cre-mediated recombination reduced TAK1 abundance to comparable levels in both sexes (Fig. 4b, c). Serial echocardiography was performed at 1 and 4 weeks post-MI. As expected for this MI model21, male mice exhibited higher mortality than females; however, within-sex survival did not differ between fbTAK1⁺ and fbTAK1⁻ mice (Fig. 4d). Body mass was modestly reduced in fbTAK1⁻ male mice, whereas heart weight and indices of pulmonary congestion were unchanged in both sexes (Supplementary Table 6). Notably, fibroblast-specific deletion of TAK1 significantly improved left ventricular ejection fraction and cardiac output in male mice at both 1- and 4-weeks post-MI, whereas no functional improvement was observed in fbTAK1⁻ females (Fig. 4e, f). Histological analysis further revealed that fbTAK1⁻ male hearts exhibited reduced total fibrotic burden and decreased transmural scar width compared with fbTAK1⁺ controls, whereas fibrosis was unchanged in female mice (Fig. 4g–j). Together, these data demonstrate that fibroblast TAK1 signaling selectively contributes to maladaptive remodeling after MI in a sex-dependent manner, with TAK1 deletion improving cardiac function and limiting fibrosis in males but not females.Fig. 4Fibroblast TAK1 deletion attenuates adverse structural and functional cardiac remodeling following myocardial infarction in male mice.a Experimental scheme of mice subjected to MI injury with echocardiography acquisition at 7 and 28 d post-MI. b, c Representative immunoblot (b) and densitometric quantification (c) of TAK1 knockdown from cardiac fibroblasts isolated from tamoxifen-treated mice. Proteins were normalized to amido black signal from stained membranes. n = 4 independent male biological replicates per group, n = 3 independent female biological replicates per group. d Kaplan-Meier survival curves for FbTAK1+ and FbTAK1- male (n = 49; 25 Cre-, 24 Cre+) and female (n = 47; 22 Cre-, 25 Cre+) mice following MI. e, f Echocardiographic quantification of ejection fraction (EF; e) and cardiac output (CO; f) at 1 and 4 wk post-MI for female and male mice. n = 17 FbTAK1+ and 12 FbTAK1- females, n = 14 FbTAK1+ and 10 FbTAK1- males. g–j Representative Picosirius red staining of transverse myocardial sections (g, h) used for quantification of scar mass (i) and width (j) from infarcted hearts. n = 15 FbTAK1+ and 11 FbTAK1- females, n = 9 FbTAK1+ and 10 FbTAK1- males. Data are mean ± SEM. Statistical procedures: Normality was assessed via Shapiro–Wilk test. Statistical tests: (c) two-way ANOVA with Šidák’s post-hoc. p = 0.0011 FbTAK1 + _males vs FbTAK1 + _females. p < 0.0001 FbTAK1 + _males vs FbTAK1-_males. p < 0.0001 FbTAK1 + _females vs FbTAK1-_females. d log-rank (Mantel-Cox) test. e, f two-way ANOVA with Šidák’s post-hoc. e Males FbTAK1+ vs FbTAK1- p = 0.0063 1 week, p = 0.0400 4 weeks. f Males FbTAK1+ vs FbTAK1- p = 0.0457 1 week, p = 0.0650 4 weeks. i, j Parametric unpaired two-sided student’s t-test or non-parametric Mann-Whitney U test were used as appropriate. i p = 0.0063, Males FbTAK1+ vs FbTAK1-. j p = 0.0189, Males FbTAK1+ vs FbTAK1-. Schematic in a was created in BioRender. Wells, C. (https://BioRender.com/6ud4rqu). Source data are provided as a Source Data file. Fibroblast TAK1 deletion attenuates adverse structural and functional cardiac remodeling following myocardial infarction in male mice. a Experimental scheme of mice subjected to MI injury with echocardiography acquisition at 7 and 28 d post-MI. b, c Representative immunoblot (b) and densitometric quantification (c) of TAK1 knockdown from cardiac fibroblasts isolated from tamoxifen-treated mice. Proteins were normalized to amido black signal from stained membranes. n = 4 independent male biological replicates per group, n = 3 independent female biological replicates per group. d Kaplan-Meier survival curves for FbTAK1+ and FbTAK1- male (n = 49; 25 Cre-, 24 Cre+) and female (n = 47; 22 Cre-, 25 Cre+) mice following MI. e, f Echocardiographic quantification of ejection fraction (EF; e) and cardiac output (CO; f) at 1 and 4 wk post-MI for female and male mice. n = 17 FbTAK1+ and 12 FbTAK1- females, n = 14 FbTAK1+ and 10 FbTAK1- males. g–j Representative Picosirius red staining of transverse myocardial sections (g, h) used for quantification of scar mass (i) and width (j) from infarcted hearts. n = 15 FbTAK1+ and 11 FbTAK1- females, n = 9 FbTAK1+ and 10 FbTAK1- males. Data are mean ± SEM. Statistical procedures: Normality was assessed via Shapiro–Wilk test. Statistical tests: (c) two-way ANOVA with Šidák’s post-hoc. p = 0.0011 FbTAK1 + _males vs FbTAK1 + _females. p < 0.0001 FbTAK1 + _males vs FbTAK1-_males. p < 0.0001 FbTAK1 + _females vs FbTAK1-_females. d log-rank (Mantel-Cox) test. e, f two-way ANOVA with Šidák’s post-hoc. e Males FbTAK1+ vs FbTAK1- p = 0.0063 1 week, p = 0.0400 4 weeks. f Males FbTAK1+ vs FbTAK1- p = 0.0457 1 week, p = 0.0650 4 weeks. i, j Parametric unpaired two-sided student’s t-test or non-parametric Mann-Whitney U test were used as appropriate. i p = 0.0063, Males FbTAK1+ vs FbTAK1-. j p = 0.0189, Males FbTAK1+ vs FbTAK1-. Schematic in a was created in BioRender. Wells, C. (https://BioRender.com/6ud4rqu). Source data are provided as a Source Data file. Fibroblast TAK1 regulates cardiac immune cell abundance after MI Based on our findings that TAK1 propagates inflammatory and stress kinase signaling in cardiac fibroblasts and promotes a highly secretory phenotype in response to inflammatory stimuli, we assessed whether fibroblast TAK1 influences immune cell abundance in the heart after MI. Following tamoxifen administration and washout, fbTAK1⁺ and fbTAK1⁻ mice underwent permanent coronary ligation, and hearts were harvested at 2, 3, and 5 d post-MI to assess immune cell composition and abundance (Fig. 5a). Flow cytometric strategies that focus on monocyte and macrophage subtypes and that delineate neutrophils using exclusion criteria22 were used to enumerate immune cells in the infarcted heart (Fig. 5b). At day 3 post-MI, the abundance of CD45⁺ leukocytes within the heart was significantly reduced in male fbTAK1⁻ mice compared with fbTAK1⁺ controls (Fig. 5c). Further stratification revealed a reduction in neutrophils and Ly6Clo monocytes in fbTAK1– hearts, whereas other immune populations were not significantly altered at this time point (Fig. 5c). In contrast, analysis of bone marrow and peripheral blood demonstrated generally higher levels of CD45pos leukocytes and monocytes in fbTAK1– mice despite their reduced abundance within the heart (Supplementary Fig. 4). These results indicate that TAK1 signaling in cardiac fibroblasts influences the abundance of immune cells in the heart after MI.Fig. 5Fibroblast TAK1 deletion reduces immune cell abundance in the heart following myocardial infarction.a Schematic of study design assessing cardiac immune cell abundances 2, 3, and 5 d post-MI. b Flow cytometric gating strategy for identification and quantification of immune cell populations. Immune cells were identified as CD45pos followed by CD64posMHCIInegLy6Chigh and Ly6Clow monocytes, neutrophils through an exclusion criteria CD45posCD64negLy6CintSSChigh. Monocyte-derived macrophages were gated as CD64posMHCIIposCCR2pos while resident macrophages were defined as CD64posMHCIIposCCR2neg. c Populations were quantified and normalized to wet tissue weight. n = 13 FbTAK1+ and 10 FbTAK1- males at day 2, 9 FbTAK1+ and 9 FbTAK1- males at day 3, 9 FbTAK1+ and 6 FbTAK1- males at day 5. Data are mean ± SEM. Statistical procedures: two-way ANOVA with Šidák’s post-hoc. Schematic in (a) was Created in BioRender. Wells, C. (https://BioRender.com/oy6sx8i). Source data are provided as a Source Data file. Fibroblast TAK1 deletion reduces immune cell abundance in the heart following myocardial infarction. a Schematic of study design assessing cardiac immune cell abundances 2, 3, and 5 d post-MI. b Flow cytometric gating strategy for identification and quantification of immune cell populations. Immune cells were identified as CD45pos followed by CD64posMHCIInegLy6Chigh and Ly6Clow monocytes, neutrophils through an exclusion criteria CD45posCD64negLy6CintSSChigh. Monocyte-derived macrophages were gated as CD64posMHCIIposCCR2pos while resident macrophages were defined as CD64posMHCIIposCCR2neg. c Populations were quantified and normalized to wet tissue weight. n = 13 FbTAK1+ and 10 FbTAK1- males at day 2, 9 FbTAK1+ and 9 FbTAK1- males at day 3, 9 FbTAK1+ and 6 FbTAK1- males at day 5. Data are mean ± SEM. Statistical procedures: two-way ANOVA with Šidák’s post-hoc. Schematic in (a) was Created in BioRender. Wells, C. (https://BioRender.com/oy6sx8i). Source data are provided as a Source Data file. TAK1 is a gatekeeper of inflammatory cardiac fibroblasts To further define how TAK1 regulates inflammatory fibroblast programming, we performed bulk RNA sequencing on cardiac fibroblasts stimulated under serum-starved conditions with bFGF, TNF-α, TGF-β, or IL-1β for 24 h, with serum-starved unstimulated fibroblasts serving as controls. Analysis of fibroblast marker expression in the control condition confirmed maintenance of a fibroblast transcriptional identity (Supplementary Table 7). Principal component analysis (PCA) revealed clear segregation of transcriptional responses based on ligand treatment, with TAK1 deletion exerting a pronounced effect on gene variance in TNF-α- and IL-1β-stimulated fibroblasts (Fig. 6a). Consistent with this observation, differential gene expression (DEG) analysis demonstrated that TAK1 deletion had the greatest impact on fibroblast transcriptional programs induced by TNF-α and IL-1β treatment, whereas relatively few TAK1-dependent changes were observed in unstimulated and bFGF-treated cells (Fig. 6b). Both TNF-α and IL-1β regulated overlapping gene sets enriched for inflammatory and immune-modulatory functions, including (anti)oxidant genes (e.g., Nos2, Sod2), chemokines and cytokines (e.g., Cxcl and Ccl family members), chemotactic growth factors (e.g., Csf2), and matrix metalloproteinases (e.g., Mmp gene family members), many of which were markedly altered by TAK1 deletion (Fig. 6c). In contrast, although approximately 4000 genes were influenced by TAK1 deletion in TGF-β-treated fibroblasts (Fig. 6b), canonical myofibroblast-associated profibrotic genes were not significantly affected (Fig. 6c). This observation is consistent with our findings that TAK1 deletion does not impair TGF-β-induced SMAD3 activation (Fig. 3i, j) or acquisition of myofibroblast markers and extracellular matrix components such as collagen and hyaluronan23 (Supplementary Fig. 5). We also found that genes regulating lipid mediators were influenced by inflammatory stimuli, with many under the control of TAK1 signaling (Fig. 6c). Collectively, these results identify TAK1 as a vital enzyme responsible for conveying extracellular cues to trigger an inflammatory transcriptional profile.Fig. 6TAK1 controls acquisition of an inflammatory fibroblast phenotype.a Principal component analysis of gene expression from LacZ or iCre transduced cells following 24 h of ligand stimulation. b Plot indicating the number of differentially expressed genes across comparison groups (log2FC > 0; q value < 0.05). c Heat map visualization of the log2FC values for genes associated with fibrotic processes, inflammatory regulation, and lipid mediator synthesis. *q < 0.01. d–g Representative immunoblots (d) and densitometric quantification (e–g) of iNOS, COX2, and MMP3 levels from TAK1fl/fl and TAK1Δ fibroblasts following 48 h of ligand stimulation. Data are mean ± SEM. Proteins were normalized to amido black signal from stained membranes. Experiments and blots were processed in parallel and normalized to an anchor protein. For a–g n = 4 male biological replicates per group. Statistical procedures: (e–g) two-way ANOVA with Šidák’s post-hoc test. e p < 0.0001 IL-1β_LacZ vs IL-1β_iCre. f p < 0.0001 IL-1β_LacZ vs IL-1β_iCre. g p = 0.0001 IL-1β_LacZ vs IL-1β_iCre. Source data are provided as a Source Data file. TAK1 controls acquisition of an inflammatory fibroblast phenotype. a Principal component analysis of gene expression from LacZ or iCre transduced cells following 24 h of ligand stimulation. b Plot indicating the number of differentially expressed genes across comparison groups (log2FC > 0; q value < 0.05). c Heat map visualization of the log2FC values for genes associated with fibrotic processes, inflammatory regulation, and lipid mediator synthesis. *q < 0.01. d–g Representative immunoblots (d) and densitometric quantification (e–g) of iNOS, COX2, and MMP3 levels from TAK1fl/fl and TAK1Δ fibroblasts following 48 h of ligand stimulation. Data are mean ± SEM. Proteins were normalized to amido black signal from stained membranes. Experiments and blots were processed in parallel and normalized to an anchor protein. For a–g n = 4 male biological replicates per group. Statistical procedures: (e–g) two-way ANOVA with Šidák’s post-hoc test. e p < 0.0001 IL-1β_LacZ vs IL-1β_iCre. f p < 0.0001 IL-1β_LacZ vs IL-1β_iCre. g p = 0.0001 IL-1β_LacZ vs IL-1β_iCre. Source data are provided as a Source Data file. Guided by both snRNA-seq data from infarcted hearts (Fig. 1) and bulk RNA-seq analysis of stimulated fibroblasts (Fig. 6), we next validated selected markers of an inflammatory cardiac fibroblast phenotype at the protein level. IL-1β stimulation robustly increased the abundance of MMP3 and inducible nitric oxide synthase (iNOS) in cardiac fibroblasts, and these responses were abolished by TAK1 deletion in male fibroblasts (Fig. 6d–f). Female cardiac fibroblasts exhibited comparable TAK1-dependent regulation of these proteins (Supplementary Fig. 6). We also examined cyclooxygenase-2 (COX2), a key enzyme involved in prostanoid synthesis and lipid mediator class-switching programs24. Notably, IL-1β treatment led to increased COX2 protein abundance in TAK1-deficient fibroblasts (Fig. 6d, g), suggesting post-transcriptional regulation of COX2 by TAK1. Consistent with this possibility, pathway analysis of RNA-seq data revealed enrichment of processes related to protein turnover and proteasomal processing following TAK1 deletion (Supplementary Fig. 7). Interestingly, although IL-1β strongly induced iNOS protein expression in a TAK1-dependent manner in vitro, Nos2 transcripts were not markedly enriched in inflammatory fibroblast subclusters in vivo after MI (see Fig. 1), indicating that the complex inflammatory milieu of the infarcted heart is not fully recapitulated by single-ligand stimulation in vitro. Finally, volcano plot analysis identified toll-like receptor 2 (Tlr2) as the most highly upregulated TLR family member in response to IL-1β, with TAK1 also regulating expression of Tlr3, Tlr4, and Tlr5 (Supplementary Fig. 8a–c). Flow cytometric analysis confirmed increased TLR2 surface expression following IL-1β stimulation (Supplementary Fig. 8d, e). Collectively, these data identify TAK1 as a central determinant of inflammatory cardiac fibroblast programming, integrating extracellular inflammatory cues to promote acquisition of immune-modulatory, matrix-remodeling, and damage-sensing properties. TAK1 diametrically regulates chemokine and lipid mediator secretion Because IL-1β converted cardiac fibroblasts to a highly secretory phenotype (Fig. 2g, h), and given data demonstrating reduced recruitment of immune cells (Fig. 5), we next examined the extent to which TAK1 regulates secretion of inflammatory mediators from cardiac fibroblasts. To this end, TAK1fl/fl fibroblasts transduced with control (LacZ) or iCre adenovirus were treated with bFGF, TGFβ, or IL-1β for 48 h, followed by a 30-min pulse of low-dose puromycin to assess newly synthesized secreted proteins. Analysis of conditioned media revealed that IL-1β robustly increased puromycin incorporation into secreted proteins, whereas TAK1 deletion markedly attenuated this response (Fig. 7a, b), indicating that TAK1 is required for inflammatory ligand-induced protein synthesis and secretion in cardiac fibroblasts.Fig. 7TAK1 signaling regulates fibroblast–immune cell communication.a, b Isolated cardiac fibroblasts transduced with LacZ or iCre adenovirus were treated with TGFβ or IL-1β for 48 h, followed by a 30-min puromycin pulse prior to conditioned medium collection. Representative immunoblots (a) and densitometric quantification (b) of secreted puromycin-labeled proteins. Experiments and blots were processed in parallel and normalized to an anchor protein. n = 4 biological replicates per group. c Heat map illustrating secreted proteins measured using quantitative cytokine/chemokine assay array (MD44; Eve Technologies) from puromycin-free conditioned medium. X = outside of standard curve, n = 4 male biological replicates per group. d Schematic of experimental strategy. Cardiac fibroblasts isolated from male and female TAK1fl/fl mice were treated with either LacZ or iCre, followed by 48 h of IL-1β treatment and conditioned medium collection. e, f Neutrophils sorted from the bone marrow of C57BL/6 J mice were allowed to migrate across a 0.5-µm transwell insert towards dilutions (10–50%) of fibroblast-derived conditioned media for 3 h. After 3 h, migrated cells were collected and counted via flow cytometry. Migrated events were normalized as percent of input control containing each respective medium. n = 3 females and 3 males. Data are mean ± SEM. Statistical procedures: two-way ANOVA with Šidák’s post-hoc. (b) p = 0.0108 IL-1β_LacZ vs IL-1β_iCre. e LacZ vs iCre p = 0.002 10%, p = 0.012 25%, p = 0.217 50%. f LacZ vs iCre p < 0.001 10%, p < 0.001 25%, p < 0.001 50%. Schematic in (d) was Created in BioRender. Wells, C. (https://BioRender.com/0y7j6bc). Source data are provided as a Source Data file. Abbreviations: G-CSF granulocyte colony-stimulating factor; GM-CSF granulocyte-macrophage colony-stimulating factor; LIF leukemia inhibitory factor; VEGF vascular endothelial growth factor; IL-3 interleukin-3; IL-6 interleukin-6; IL-7 interleukin-7; IL-10 interleukin-10; IL-15 interleukin-15; IL-12p70 interleukin-12 p70; IL-9 interleukin-9; IFNβ-1 interferon beta-1; KC keratinocyte-derived chemokine; LIX lipopolysaccharide-induced CXC chemokine; IP-10 interferon gamma-induced protein 10; MCP-1, monocyte chemoattractant protein-1; MCP-5 monocyte chemoattractant protein-5; RANTES regulated on activation, normal T cell expressed and secreted; MIP-3α macrophage inflammatory protein-3 alpha; MIP-1β macrophage inflammatory protein-1 beta. TAK1 signaling regulates fibroblast–immune cell communication. a, b Isolated cardiac fibroblasts transduced with LacZ or iCre adenovirus were treated with TGFβ or IL-1β for 48 h, followed by a 30-min puromycin pulse prior to conditioned medium collection. Representative immunoblots (a) and densitometric quantification (b) of secreted puromycin-labeled proteins. Experiments and blots were processed in parallel and normalized to an anchor protein. n = 4 biological replicates per group. c Heat map illustrating secreted proteins measured using quantitative cytokine/chemokine assay array (MD44; Eve Technologies) from puromycin-free conditioned medium. X = outside of standard curve, n = 4 male biological replicates per group. d Schematic of experimental strategy. Cardiac fibroblasts isolated from male and female TAK1fl/fl mice were treated with either LacZ or iCre, followed by 48 h of IL-1β treatment and conditioned medium collection. e, f Neutrophils sorted from the bone marrow of C57BL/6 J mice were allowed to migrate across a 0.5-µm transwell insert towards dilutions (10–50%) of fibroblast-derived conditioned media for 3 h. After 3 h, migrated cells were collected and counted via flow cytometry. Migrated events were normalized as percent of input control containing each respective medium. n = 3 females and 3 males. Data are mean ± SEM. Statistical procedures: two-way ANOVA with Šidák’s post-hoc. (b) p = 0.0108 IL-1β_LacZ vs IL-1β_iCre. e LacZ vs iCre p = 0.002 10%, p = 0.012 25%, p = 0.217 50%. f LacZ vs iCre p < 0.001 10%, p < 0.001 25%, p < 0.001 50%. Schematic in (d) was Created in BioRender. Wells, C. (https://BioRender.com/0y7j6bc). Source data are provided as a Source Data file. Abbreviations: G-CSF granulocyte colony-stimulating factor; GM-CSF granulocyte-macrophage colony-stimulating factor; LIF leukemia inhibitory factor; VEGF vascular endothelial growth factor; IL-3 interleukin-3; IL-6 interleukin-6; IL-7 interleukin-7; IL-10 interleukin-10; IL-15 interleukin-15; IL-12p70 interleukin-12 p70; IL-9 interleukin-9; IFNβ-1 interferon beta-1; KC keratinocyte-derived chemokine; LIX lipopolysaccharide-induced CXC chemokine; IP-10 interferon gamma-induced protein 10; MCP-1, monocyte chemoattractant protein-1; MCP-5 monocyte chemoattractant protein-5; RANTES regulated on activation, normal T cell expressed and secreted; MIP-3α macrophage inflammatory protein-3 alpha; MIP-1β macrophage inflammatory protein-1 beta. To define the identity of TAK1-dependent secreted factors, we next quantified chemokines and cytokines in conditioned media using multiplex protein arrays. TAK1 deletion had minimal effects on cytokine or chemokine abundance in serum-starved fibroblasts, whereas TGF-β increased VEGF secretion, which was further augmented by TAK1 deletion (Fig. 7c). In contrast, IL-1β stimulation induced robust secretion of growth factors (G-CSF, GM-CSF) and chemokines (KC, LIX, IP-10, MCP-1, MCP-5, RANTES, MIP-3α, eotaxin) known to promote immune cell recruitment and activation. Deletion of TAK1 suppressed the majority of IL-1β-induced growth factors and chemokines, with leukemia inhibitory factor (LIF) representing a notable exception (Fig. 7c). Together, these findings demonstrate that TAK1 positively regulates secretion of pro-inflammatory chemoattractant proteins in cardiac fibroblasts. To determine whether TAK1-dependent changes in the fibroblast secretome have functional consequences for immune cell recruitment, as is suggested by data in Fig. 5, we performed neutrophil chemotaxis assays using conditioned media from IL-1β-stimulated fibroblasts (Fig. 7d). Conditioned media from TAK1-replete fibroblasts induced robust neutrophil migration, whereas media from TAK1-deficient fibroblasts significantly attenuated chemotaxis in both male and female cells (Fig. 7e, f). This effect became more pronounced with serial dilution of conditioned media, consistent with saturation of neutrophil migratory capacity at high chemoattractant concentrations. These results indicate that TAK1-dependent fibroblast secretory programs directly influence neutrophil chemotaxis. In addition to protein mediators, lipid mediators are crucial in both initiating and quelling inflammation25. Guided by transcriptomic analyses indicating TAK1-dependent regulation of lipid mediator biosynthetic enzymes (see Fig. 6c), we next examined the effects of TAK1 deletion on lipid mediator production. We first assessed cyclooxygenase-2 (COX2), a key enzyme in prostanoid synthesis and lipid mediator class-switching24. Similar to findings in Fig. 6d, IL-1β modestly increased COX2 abundance in TAK1-replete fibroblasts, whereas COX2 protein levels were markedly elevated in TAK1-deficient fibroblasts following IL-1β stimulation (Fig. 8a, b), suggesting post-transcriptional regulation of COX2 by TAK1.Fig. 8IL-1β modulates lipid mediator synthesis and secretion in cardiac fibroblasts in a TAK1-dependent manner.a, b Representative immunoblot (a) and densitometry quantification (b) of cyclooxygenase 2 (COX2) abundance from TAK1fl/fl and TAK1Δ fibroblasts following 48 h of IL-1β stimulation. Data are mean ± SEM. Proteins were normalized to amido black signal from stained membranes. n = 5 male biological replicates per group. c–e Conditioned medium was collected for LC-MS/MS analysis of secreted lipid mediators: unsupervised PCA plot (c), biplot (d), and heatmap (e). f schematic of proposed function. X = not detected, n = 3 male biological replicates per group. Statistical procedures: (b, f) two-way ANOVA with Šidák’s post-hoc test; (b) IL-1β_LacZ vs IL-1β_iCre p < 0.0001. (e) *# p < 0.05, *IL-1β (LacZ vs iCre), #CTRL (LacZ vs iCre). Schematic in f was Created in BioRender. Wells, C. (https://BioRender.com/3d2wu0d). Source data are provided as a Source Data file. Abbreviations: AA arachidonic acid; PGE2 prostaglandin E2; 15-keto-PGE2 15-keto-prostaglandin E2; PGD2 prostaglandin D2; PGJ2 prostaglandin J2; 15-deoxy-PGJ2 15-deoxy-prostaglandin J2; PGF2a prostaglandin F2α; 8-iso-PGF2a, 8-isoprostaglandin F2α; 15-HETE 15-hydroxyeicosatetraenoic acid; LXB4 lipoxin B4; LXA4 lipoxin A4; 15(R)-LXA4 15(R)-lipoxin A4; 5,15-diHETE 5,15-dihydroxyeicosatetraenoic acid; 12-HETE 12-hydroxyeicosatetraenoic acid; 5-HETE 5-hydroxyeicosatetraenoic acid; 6-trans-LTB4 6-trans-leukotriene B4; 6-trans,12-epi-LTB4 6-trans,12-epi-leukotriene B4; LTB4 leukotriene B4; DHA docosahexaenoic acid; 4-HDHA 4-hydroxydocosahexaenoic acid; 17-HDHA 17-hydroxydocosahexaenoic acid; RvD1 resolvin D1; RvD4 resolvin D4; 14-HDHA 14-hydroxydocosahexaenoic acid; EPA eicosapentaenoic acid; 12-HEPE 12-hydroxyeicosapentaenoic acid; 18-HEPE 18-hydroxyeicosapentaenoic acid; RvE1 resolvin E1; RvE2 resolvin E2; RvE4 resolvin E4; 15-HEPE 15-hydroxyeicosapentaenoic acid; 5-HEPE 5-hydroxyeicosapentaenoic acid; LXA5 lipoxin A5; 1415-EET, 14,15-epoxyeicosatrienoic acid; 17,18-EpETE 17,18-epoxyeicosatetraenoic acid; DPA, docosapentaenoic acid. IL-1β modulates lipid mediator synthesis and secretion in cardiac fibroblasts in a TAK1-dependent manner. a, b Representative immunoblot (a) and densitometry quantification (b) of cyclooxygenase 2 (COX2) abundance from TAK1fl/fl and TAK1Δ fibroblasts following 48 h of IL-1β stimulation. Data are mean ± SEM. Proteins were normalized to amido black signal from stained membranes. n = 5 male biological replicates per group. c–e Conditioned medium was collected for LC-MS/MS analysis of secreted lipid mediators: unsupervised PCA plot (c), biplot (d), and heatmap (e). f schematic of proposed function. X = not detected, n = 3 male biological replicates per group. Statistical procedures: (b, f) two-way ANOVA with Šidák’s post-hoc test; (b) IL-1β_LacZ vs IL-1β_iCre p < 0.0001. (e) *# p < 0.05, *IL-1β (LacZ vs iCre), #CTRL (LacZ vs iCre). Schematic in f was Created in BioRender. Wells, C. (https://BioRender.com/3d2wu0d). Source data are provided as a Source Data file. Abbreviations: AA arachidonic acid; PGE2 prostaglandin E2; 15-keto-PGE2 15-keto-prostaglandin E2; PGD2 prostaglandin D2; PGJ2 prostaglandin J2; 15-deoxy-PGJ2 15-deoxy-prostaglandin J2; PGF2a prostaglandin F2α; 8-iso-PGF2a, 8-isoprostaglandin F2α; 15-HETE 15-hydroxyeicosatetraenoic acid; LXB4 lipoxin B4; LXA4 lipoxin A4; 15(R)-LXA4 15(R)-lipoxin A4; 5,15-diHETE 5,15-dihydroxyeicosatetraenoic acid; 12-HETE 12-hydroxyeicosatetraenoic acid; 5-HETE 5-hydroxyeicosatetraenoic acid; 6-trans-LTB4 6-trans-leukotriene B4; 6-trans,12-epi-LTB4 6-trans,12-epi-leukotriene B4; LTB4 leukotriene B4; DHA docosahexaenoic acid; 4-HDHA 4-hydroxydocosahexaenoic acid; 17-HDHA 17-hydroxydocosahexaenoic acid; RvD1 resolvin D1; RvD4 resolvin D4; 14-HDHA 14-hydroxydocosahexaenoic acid; EPA eicosapentaenoic acid; 12-HEPE 12-hydroxyeicosapentaenoic acid; 18-HEPE 18-hydroxyeicosapentaenoic acid; RvE1 resolvin E1; RvE2 resolvin E2; RvE4 resolvin E4; 15-HEPE 15-hydroxyeicosapentaenoic acid; 5-HEPE 5-hydroxyeicosapentaenoic acid; LXA5 lipoxin A5; 1415-EET, 14,15-epoxyeicosatrienoic acid; 17,18-EpETE 17,18-epoxyeicosatetraenoic acid; DPA, docosapentaenoic acid. To assess lipid mediator output, we performed targeted LC/MS lipidomics on conditioned medium, examining the effects of IL-1β and TAK1 expression on lipid mediator secretion. PCA revealed separation of the experimental groups, with PC1 and PC2 accounting for 84.1% of the total variance (Fig. 8c). Metabolites with the largest loadings on these components were interpreted as the principal contributors to this separation. PGD2, 12-HEPE, 18-HEPE, 17,18-EpETE, and EPA loaded toward the upper-left quadrant, whereas LXA4, 15(R)-LXA4, PGJ2, PGE2, and PGF2a loaded toward the lower-left quadrant, indicating that these features primarily distinguished samples on the negative-PC1 side of the ordination, with PGE2 and PGF2a contributing strongly to negative-PC2 separation (Fig. 8d). In parallel, heatmap analysis showed that IL-1β reduced multiple lipid mediators and their precursor fatty acids, including arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acid (Fig. 8e), consistent with the possibility that inflammatory signaling suppresses lipid mediator synthesis in part through reduced substrate availability. TAK1 deletion rescued the IL-1β-induced reduction in lipid mediator abundance and increased lipid mediator levels under basal conditions (Fig. 8e). Collectively, these findings demonstrate that TAK1 exerts opposing regulatory effects on fibroblast secretory outputs: it promotes inflammatory chemokine and cytokine secretion while restraining lipid mediator production (Fig. 8f). This functional asymmetry positions TAK1 as a key regulator of the balance between inflammatory amplification and resolution programs in cardiac fibroblasts. Discussion Tissue repair depends on coordinated communication between different cell types to facilitate removal of cellular debris, synthesis of extracellular matrix, and tissue remodeling. Although fibroblasts are recognized as central mediators of these processes, it has remained unclear how inflammatory signaling within fibroblasts coordinates communication with immune cells in response to tissue injury. Here, in the context of MI, we identify TAK1 signaling as a gatekeeper of an inflammatory cardiac fibroblast phenotype. Deletion of TAK1 in fibroblasts improved cardiac structural and functional remodeling after MI in male mice and was associated with diminished post-MI abundance of neutrophils and resident macrophages within the heart. These effects were sexually dimorphic, with female mice showing no functional or fibrotic benefit. Moreover, TAK1 differentially regulated the synthesis and secretion of chemokines and (anti)inflammatory lipid mediators in opposing directions, promoting chemokine production while restraining lipid mediator synthesis. Collectively, these findings identify fibroblast TAK1 as a molecular switch that coordinates inflammatory amplification versus resolution during cardiac repair, thereby clarifying the nature and function of inflammatory cardiac fibroblasts in post-injury remodeling. Inflammatory signaling has been a focus of numerous therapeutic efforts to combat heart disease. Several studies demonstrate that blunting IL-1 signaling or its downstream targets (e.g, NF-κB) attenuates cardiac dysfunction3,4,8,26. Nevertheless, how inflammatory signaling is integrated within cardiac fibroblasts and how this integration shapes tissue-level responses to injury has remained poorly defined. Our investigation of fibroblast-resident TAK1 reveals its role as a central signaling node that integrates diverse inflammatory cues to drive inflammatory cardiac fibroblast differentiation and function. Using distinct models of cardiac stress, we found that fibroblast TAK1 signaling is critical for remodeling after MI but dispensable for remodeling induced by chronic pressure overload. These findings support the notion that fibroblast TAK1 signaling is particularly important in settings of robust inflammatory activation, such as MI. In contrast, remodeling driven by sustained mechanical stress, typically associated with a lower inflammatory burden18,19, appears to proceed independently of TAK1. Consistent with this interpretation, fibroblast TAK1 deletion improved cardiac function as early as one-week post-MI in male mice, with benefits persisting throughout the four-week study period, and also attenuated post-MI fibrosis. In contrast, TAK1 deletion had no salutary effects in female mice, positioning fibroblast TAK1 as a sexually dimorphic regulator of maladaptive post-infarct remodeling. The sexually dimorphic effects observed in vivo were notable, particularly given that female cardiac fibroblasts responded to inflammatory stimuli similarly to male fibroblasts in vitro. These findings suggest that differences in post-MI remodeling between sexes likely reflect broader differences in immune responses rather than intrinsic fibroblast signaling capacity. Indeed, prior studies have demonstrated sex-dependent differences in post-MI inflammation27, including reduced neutrophil recruitment and altered macrophage polarization in females, which may diminish dependence on fibroblast-driven inflammatory amplification. Thus, fibroblast TAK1 signaling appears to be a critical determinant of maladaptive inflammatory remodeling in males, whereas effective repair in females may proceed through mechanisms less reliant on this pathway. Mechanistically, our data indicate that TAK1 propagates IL-1β- and TNF-α-mediated inflammatory signaling in cardiac fibroblasts without affecting canonical TGF-β-SMAD signaling. This signaling specificity suggests that TAK1 primarily governs acquisition of inflammatory properties rather than directly controlling myofibroblast differentiation. In this context, TAK1 does not simply permit fibroblast activation, but instead regulates the magnitude and composition of inflammatory outputs that define the inflammatory fibroblast state. An inflammatory fibroblast phenotype would be expected to rapidly synthesize and secrete cytokines, chemokines, and growth factors; sense molecular patterns associated with tissue injury; and secrete proteases that remodel extracellular matrix6. Consistent with this model, TAK1 exerted robust control over the synthesis and secretion of chemokines, growth factors, matrix metalloproteinases, and lipid mediators. IL-1β-induced secretory activity was particularly pronounced, with TAK1-dependent production of chemotactic factors such as G-CSF, GM-CSF, MCP1, MCP5, LIX, KC, and MIP-3α. In the infarcted heart, fibroblast-specific TAK1 deletion reduced the abundance of CD45⁺ immune cells, particularly neutrophils and Ly6Clo monocytes, and conditioned media from TAK1-deficient fibroblasts exhibited diminished neutrophil chemotactic capacity. Although canonical TGF-β signaling was unaffected, enhanced VEGF secretion in TAK1-deficient fibroblasts suggests that TAK1 may also modulate non-canonical TGF-β outputs, potentially influencing angiogenic responses during repair. An important finding of this study is that TAK1 signaling differentially regulates chemokine and lipid mediator output in cardiac fibroblasts. Although TAK1 activity is required for robust chemokine synthesis and secretion, it concurrently limits the production of lipid mediators relevant to post-MI responses28, such as prostaglandins, lipoxins, and resolvins. Consistent with this model, IL-1β stimulation reduced not only downstream lipid mediator products but also their metabolic substrates, including arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid, indicating suppression of overall lipid mediator flux. Genetic deletion of TAK1 reversed these effects and augmented lipid mediator production even under basal conditions, suggesting that TAK1 limits mediator synthesis by restricting substrate availability and biosynthetic capacity. Transcriptomic analyses implicating TAK1-dependent regulation of phospholipases and the proteasomal system (e.g., see Supplementary Fig. 7) support a model in which TAK1 influences lipid mediator synthesis through post-transcriptional mechanisms and proteostatic control. Given that IL-1β induces phospholipase A2 expression and activity via MAPK and NF-κB signaling29,30, TAK1-dependent control of phospholipases may provide a mechanistic link between inflammatory stimulation and substrate mobilization for lipid mediator synthesis. The observation that IL-1β and TAK1 exert non-redundant effects on COX2 abundance indicates an additional layer of regulatory control over lipid mediator production. Although IL-1β provides a potent upstream stimulus for COX2 (Ptgs2) gene induction, our data indicate that TAK1 limits the steady-state accumulation of COX2 protein under inflammatory conditions. Deletion of TAK1 amplified IL-1β-dependent increases in COX2 abundance, consistent with impaired protein turnover rather than selective transcriptional induction. Consistent with this interpretation, TAK1 deletion diminished the expression of multiple genes associated with proteasomal function, a pathway known to regulate COX2 stability and degradation31. These findings support a role for TAK1 in constraining lipid mediator synthesis and raise the possibility that altered COX2 regulation may also contribute to lipid mediator “class-switching”, which has been proposed to facilitate both inflammation and resolution as well as tissue repair32,33. Collectively, these findings indicate that TAK1 dictates the cadence of inflammatory and resolution programs: early TAK1 activation amplifies chemokine-driven immune cell recruitment, whereas subsequent attenuation of TAK1 signaling permits lipid mediator production that facilitates resolution and tissue repair. Our findings refine existing models of fibroblast function in post-MI remodeling. Recent studies have shown that IL-1β derived from CX3CR1⁺ or CCR2⁺ immune cells promote emergence of inflammatory fibroblast populations3,4. Building on this framework, our data support the concept that fibroblasts act as sensor and amplifier cells that integrate inflammatory signals and regulate immune cell recruitment, matrix remodeling, and resolution. The diametric regulation of chemokine and lipid mediator secretion by TAK1 further suggests that inflammatory fibroblasts may dynamically modulate immune cell behavior over time, initially promoting recruitment and subsequently facilitating resolution once sufficient wound healing has occurred. Although this study shows the importance of TAK1 in regulating the inflammatory fibroblast phenotype and cardiac remodeling after MI, there are several limitations and questions that remain. For example, Amrute et al. showed that IL-1β contributes to the emergence of a fibroblast population characterized by elevated periostin expression3; however, our study, as well as others8, indicate that IL-1β suppresses TGF-β-induced periostin expression (and α-SMA). It is likely that, in addition to inflammatory stimuli such a IL-1β and TNF-α, a panoply of paracrine mediators contribute to the ultimate phenotype that fibroblasts assume in the post-infarcted heart and that, like macrophages34, fibroblasts can assume a spectrum of unique phenotypes and state spaces35. In addition, although we confirmed some of the findings from RNA sequencing data (e.g., cyclooxygenase 2, MMP3), there are many transcriptional changes that were not confirmed at the gene or protein expression level. Another limitation is that our study did not assess the infiltration of the infarct with fibroblasts, and it remains possible that TAK1 deletion in the context of MI may have been associated with fewer fibroblasts migrating to the infarct region. In addition, while we demonstrate reduced immune cell abundance in the infarcted heart following fibroblast-specific TAK1 deletion, we did not directly assess immune cell phenotypic states or functional programming. Thus, it remains unclear whether TAK1-dependent fibroblast signaling regulates not only immune cell recruitment but also immune cell polarization or effector function within the post-infarct microenvironment. Additionally, floxed littermates were used as controls for fibroblast-specific TAK1 deletion. While inclusion of a Cre only control could further isolate potential Cre effects, prior studies using the Col1a2-CreERT driver have shown that Cre transgene expression does not alter basal cardiac structure or function36, supporting the interpretation that the observed phenotypes reflect loss of TAK1 rather than Cre expression. Finally, surgery-associated inflammatory signaling cannot be fully excluded, as sham-operated mice were not included for MI studies. Nevertheless, the observed genotype-dependent effects arose in the setting of confirmed infarction and post-MI remodeling, making it unlikely that sham-level injury was the principal driver of the phenotype. Taken together, our findings underscore the unique functional capacity of cardiac fibroblasts to sense inflammatory cues and adopt specialized inflammatory states that shape tissue-level repair. We identify TAK1 as a central regulator of this process, coordinating inflammatory amplification and resolution through opposing effects on protein and lipid mediator secretion. In vivo, fibroblast TAK1 activity appears detrimental to effective repair following MI, particularly in males. Given its essential roles in stress and immune signaling, therapeutic targeting of TAK1 would require careful consideration of timing, cellular specificity, and host defense; nevertheless, our findings identify fibroblast TAK1 as a potentially actionable regulatory node for limiting maladaptive inflammatory remodeling after myocardial infarction. Methods Study design and ethical approval All experimental protocols were reviewed and approved by the University of Louisville Institutional Animal Care and Use Committee, and all animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals. Investigators were blinded to genotype during surgical procedures, echocardiographic acquisition and analysis, histological analysis, and flow cytometry. Inclusion and exclusion criteria were defined a priori. For myocardial infarction (MI) studies, echocardiographic confirmation of infarction by regional wall motion abnormality was required for inclusion, and mice that expired within the first 24 h after surgery were excluded in accordance with published guidelines. For transverse aortic constriction (TAC), only mice exhibiting a stenotic pressure gradient >40 mmHg were included. Primary in vivo comparisons were performed between fbTAK1⁺ and fbTAK1⁻ mice within each sex; cross-sex comparisons were not powered and were not emphasized. Mice and tamoxifen-induced fibroblast-specific TAK1 deletion A fibroblast-specific TAK1 deletion model was generated by crossing Col1a2-CreERT⁺/⁻ mice (Jackson Laboratory) with TAK1fl/fl mice37. All mice were on a C57BL/6J background, and genotypes were confirmed by PCR analysis of tail DNA. Mice were housed in a pathogen-free facility under controlled conditions (24 °C, 44–65% relative humidity, 12-h light/dark cycle) and maintained on standard chow (LabDiet 5010). For induction of TAK1 deletion, mice received either intraperitoneal injections of tamoxifen (75 mg/kg body weight; Sigma-Aldrich, T5648) for 5 consecutive days followed by a 5-day washout, or tamoxifen-containing chow ( ~ 400 mg/kg diet; Envigo TD.130859) for 2 weeks followed by a 1-week washout prior to experimental intervention. Both routes of tamoxifen administration produced comparable levels of TAK1 deletion in isolated cardiac fibroblasts. General surgical procedures All surgeries were performed in a dedicated surgical suite. Mice were anesthetized with ketamine (50 mg/kg) and pentobarbital (50 mg/kg), orally intubated, and mechanically ventilated with oxygen. Body temperature was maintained throughout surgery. Analgesia (meloxicam, 20 mg/kg) was administered prior to recovery and again at 24 and 48 h post-surgery. Surgeons were blinded to genotype. Transverse aortic constriction In a dedicated laboratory space, adult, 12–18-week-old, male and female Cre+/–:TAK1fl/fl and TAK1fl/fl littermate mice were acclimated for at least 1 h prior to transverse aortic constriction surgery, as described38,39. Briefly, mice were anesthetized with 50 mg/kg ketamine and 50 mg/kg pentobarbital. Subsequently, they were orally intubated and ventilated with oxygen. A skin incision was made left of the midline skin to expose the chest. Using a cautery tip, a small incision was made between the 3rd and 4th rib on the left side of the chest. A 7-0 silk suture was then looped around the aorta between the brachiocephalic and left common carotid arteries. The suture was tied around a 27-gauge needle positioned adjacent to the aorta to create a constriction of reproducible diameter. The needle was quickly removed, and constriction was visualized before the chest was closed with a 4-0 monofilament suture. Mice were extubated upon recovery of spontaneous breathing and allowed to recover in a warm clean cage. Analgesia (meloxicam, 20 mg/kg) was provided prior to the recovery as well as at 24 and 48 h post-surgery. The surgeon was blinded to mouse genotype. Only mice with a stenotic pressure gradient of ≥40 mmHg were considered for subsequent analysis (see Source Data). Non-reperfused myocardial infarction In a dedicated laboratory space, adult, 12–18-week-old, male and female Cre+/–:TAK1fl/fl and TAK1fl/fl littermate mice were acclimated for at least 1 h prior to non-reperfused myocardial infarction, as described23,40,41. Briefly, mice were first anesthetized through intra-peritoneal injections of (pentobarbital, 50 mg/kg; ketamine, 50 mg/kg) before surgery. Subsequently, they were orally intubated and ventilated with oxygen. Using a 7-0 silk suture, the left coronary artery was permanently ligated and then the chest wall was sutured closed. Mice were extubated only after the recovery of spontaneous breathing, allowed to recover in a warm clean cage, and analgesia (meloxicam, 20 mg/kg) was provided prior to the recovery as well as at 24 and 48 h post-surgery. The surgeon was blinded to mouse genotype. Echocardiography confirmation of infarction, defined by the presence of regional wall motion asystole, was required for inclusion in subsequent analysis. In accordance with guidelines on MI in mice21, mice that expired within the first 24 h after surgery were excluded from the study. Postoperative animal care Research team and veterinary staff monitored the animals twice daily during the 1st week after surgery and then twice weekly throughout the duration of the study. Health was gauged by temperature, body weight, food and water intake, and general assessment of respiratory status, ambulation, arousal, posture, and surgical site healing. Indications for euthanasia include loss of body weight ( ≥ 15%), respiratory stress, suture site dehiscence, hunched posture, surgical site infections, vocalization to touch, or other clinical signs of distress as listed in the University of Louisville Institutional Animal Care and Use Committee Humane Endpoints Policy. Echocardiography acquisition and analysis At the designated times, cardiac structure and function were assessed through transthoracic echocardiography (Vevo 3100, Visual Sonics) while under anesthetic (2% isoflurane). Ventricular wall thickness was obtained with M-mode images through parasternal long axis (PLAX) view. Reported measurements included left ventricular (LV) interior diameter (LVID), LV mass (corrected), LV posterior wall thickness, and LV anterior wall thickness near the border zone. Each parameter represents the average of four measurements and corrected LV mass was calculated from the formula: (1.053 × [(LV interior diameter;d + LV posterior wall;d + intravenous septum;d)3 – LV interior diameter;d3]) × 0.8, where d indicates diastole. For uninjured and TAC hearts, two-dimensional images viewed in B-Mode from the parasternal long axis (PLAX) were used to make measurements for left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV), from which we calculated stroke volume (SV), cardiac output (CO), ejection fraction (EF). Six measurements were taken and averaged for final outputs. For myocardial infarction studies, Simpson’s method with a PLAX and three parasternal short axis views was used to obtain B-mode images for measuring volumetric (LVEDV, LVESV) and cardiac performance (SV, CO, EF, HR) indices with five measurements taken at different ventricular planes and averaged42,43. An apical four chamber view in Pulsed Wave (PW) Doppler was used for measurement of isovolumic relaxation time (IVRT) for all studies; reported values were averaged from nine individual measurements. The sonographer and analyzer were blinded to mouse genotype. Tissue collection, histopathology, and scar quantification At the conclusion of the study, mice were euthanized and hearts excised and arrested in diastole with ice-cold 2% potassium chloride. Each heart was then sectioned into 2-mm cross-sectional segments and fixed in 10% formalin prior to being embedded in paraffin, sectioned (4 µm), and mounted. Slides were then deparaffinized and rehydrated before staining. Picrosirius red staining (Picric Acid, Sigma, P6744; Direct Red 80, Sigma, 365548) was used to detect collagen in intact sections from base to apex. Sections were visualized using a Keyence BZ-X800 microscope. Acquired images were then analyzed using the Keyence software with customized Matlab macros. The microscopist was blinded to group assignments. Total scar size (mass in mg) was calculated by summation of scar masses corresponding to each transverse myocardial segment (base to apex; 4 segments per heart): scar mass (mg) = [section mass (mg)] x [scar area (μm2)/section area (μm2)]. Infarct width was manually measured via ImageJ in midpapillary level sections. Hydroxyproline assay Harvested hearts were perfused with PBS and immediately frozen. Frozen hearts were pulverized, and 10 mg was transferred to a pressure-tight polypropylene vial. Samples were then processed according to manufacturer’s instructions (Sigma-Aldrich, MAK008). Flow cytometry Post-MI hearts were harvested, and PBS was perfused through the aorta for 5 min. Then, the aorta, atria, and excess adipose were excised from the ventricles. The tissue was then finely minced with a razor blade and digested in PBS with collagenase II (1200 U/mL, Worthington Biochemical) with gentle agitation for 45 min at 37oC. Collagenase was deactivated by washing with PBS and cells were further separated using a 30% Percoll gradient (Sigma Aldrich, P4937). After centrifugation, debris was aspirated, and cell pellets were washed with PBS. Cells were stained with antibodies for 30 min at 4oC in the dark: APC anti-mouse Ly6C (Biolegend, 128016), BV 421 anti-mouse CD192/CCR2 (Biolegend, 150605), PE anti-mouse CD64 (Biolegend, 139304), PE-Cyanine7 monoclonal antibody CD45 (Thermo Fisher, 25-0451-82), FITC monoclonal antibody MHC class II I-Ab (Thermo Fisher, 11-5320-82). Finally, cells were washed twice with PBS and resuspended in 1 mL of PBS for flow cytometry. Immune cells were first gated as CD45pos followed by CD64posMHCIInegLy6Chigh and Ly6Clow monocytes and neutrophils through an exclusion criteria CD45posCD64negLy6CintSSChigh22. Monocyte-derived macrophages were gated as CD64posMHCIIposCCR2pos while resident macrophages were defined as CD64posMHCIIposCCR2neg. Subsequent data analysis was completed using FlowJo, LLC. Primary cardiac fibroblast isolation and culture Cardiac fibroblasts were isolated from naïve, adult C57BL/6 J wild type (Jackson Laboratory) and TAK1fl/fl mice37. Briefly, after euthanasia, the hearts were excised, and the aorta was cannulated using a 23-gauge needle. Ice-cold PBS was perfused through the aorta, and any excess aorta and adipose tissue were carefully excised from the heart before mincing it with a razor blade under sterile conditions. The minced tissue was then digested in a solution of type II collagenase (prepared in sterile PBS, 5000U/heart, Worthington, 46H16739) for 45 min at 37 °C with gentle agitation. Collagenase activity was then quenched with culture medium [i.e., Dulbecco’s Modified Eagle’s Medium/F12 GlutaMax (DMEM, Gibco 10565018) containing 10% fetal bovine serum (FBS, VWR 76324-888), 1% penicillin/streptomycin/amphotericin B (Sigma, A5955), 1% insulin transferrin selenium (ITS-G, Gibco 41400045), and 20 ng/ml human bFGF (Peprotech 100-18B)] and the mixture was then centrifuged at 500 g for 10 min. Supernatants were aspirated, and cell pellets were resuspended in culture media before being passed through a 70 µm cell strainer. The cells were then plated in a T-75 cell culture flask (10062-860, VWR) and incubated at 37 °C in 5% CO2. Media was changed after 2 h and again after 24 h. For in vitro studies, fibroblasts were used at passage 1 and serum-starved in DMEM/F12 GlutaMax media (ThermoFisher) without any supplementation prior to treatment with TGFβ (10 ng/ml, PeproTech, 100-21), bFGF (20 ng/ml, PeproTech, 100-18 C), IL-1β (15 ng/ml, PeproTech, 200-01B), or TNF-α (10 ng/ml, PeproTech, 300-01 A). When appropriate, TAK1 inactivation in isolated cardiac fibroblasts from TAK1fl/fl mice was induced prior to ligand stimulation with ad-CMV-iCre (Vector Biolabs, 1045) or vector control ad-CMV-LacZ (Vector Biolabs, 1080). Following 48 h of virus transduction, cells were subsequently cultured in serum-free medium for experimentation. SUnSET assay Following experimental treatment, puromycin (Millipore, P8833) was added to the cell culture medium (1 μM final concentration) for 30 min prior to conditioned medium collection. Newly synthesized and secreted puromycin-labeled proteins were detected through immunoblot visualization using primary antibody anti-puromycin (1:10,000, Millipore, MABE343). Western blot analysis Following experimental treatments, conditioned media was collected and/or total protein was harvested after washing cells with ice-cold PBS. PBS was aspirated and cells were then scraped with a rubber policeman in lysis buffer (20 mM HEPES, 110 mM KCl, 1 mM EDTA, 1% IGE-PAL, and 0.1% SDS, pH 7.0) containing protease inhibitor cocktail (Sigma-Aldrich, P8340). The cell lysates were incubated on ice for 30 min and then centrifuged at 20,000 g for 20 min. The supernatants were then carefully removed and saved for total protein measurements (Lowry assay) and Western blotting. Conditioned medium and cell lysate protein samples were mixed with Laemmli sample buffer (125 mM Tris-HCl, 10% SDS, 50% glycerol, 0.05% bromophenol blue, pH 6.8) and incubated at 95oC for 5 min. Each sample was then loaded on acrylamide/bis SDS-PAGE gels for electrophoresis at 120 V. SDS-PAGE-resolved proteins were then transferred overnight onto a PVDF membrane (Cytiva, 10600021) at 4 °C at 20 V for 16 h. Subsequently, membranes were blocked for 1 h at room temperature with Tris-buffered saline containing Tween-20 (TBS-T) and 5% bovine serum albumin (Sigma-Aldrich, A7906). Membranes were probed with primary antibodies overnight at 4 °C. The following day, membranes were washed three times using TBS-T and then incubated with secondary antibody for 1.5 h. Membranes were then washed three times with TBS-T before exposure to Pierce™ ECL Plus Western Blotting Substrate (Thermo Scientific, 32132) and imaging on a ChemiDoc imager (BioRad). Protein was normalized to total lane protein with an amido black stain, and parallel blots were normalized to an anchor protein. The primary antibodies used include: anti-COL1A1 (1:20,000; Thermo Fisher, PA5-29569), anti-Periostin (1:5000; Millipore, ABT253), anti-α-smooth muscle actin (1:30,000; Cell Signaling, 19245S), anti-MMP3 (1:2000, Invitrogen, MA5-42477), anti-COX2 (1:2000, Cell Signaling, 12282), anti-iNOS (1:2000, Millipore, 06-573), anti-TAK1 (1:500, Cell Signaling, 5206), anti-p-NFκB p65 (1:1000) Cell Signaling, 3033), anti-NFκB p65 (1:1000, Cell Signaling, 8242), anti-p-SAPK/JNK (1:1000, Cell Signaling, 4668), anti-SAPK/JNK (1:1000, Cell Signaling, 9252), anti-p-p38 (1:5000, Cell Signaling, 4511), anti-p38 (1:5000, Cell Signaling, 8690), anti-IκBα (1:2000, Cell Signaling, 9242), anti-p-Smad3 (1:2000, Cell Signaling, 9520), anti-Smad3 (1:2000, Cell Signaling, 9523 T). Secondary antibody included anti-rabbit IgG HRP-linked (1:2,500; Cell Signaling, 7074) and anti-mouse IgG HRP-linked (1:2,500; Cell Signaling, 7076). Multiplex cytokine and chemokine analysis To profile secreted proteins in the conditioned medium, we used Luminex® xMAP® technology to quantitatively and simultaneously detect forty-four mouse cytokines, chemokines and growth factors. The multiplexing analysis was performed by Eve Technologies Corporation (Calgary, Alberta, Canada) using the Luminex® 200™ system (Luminex Corporation/DiaSorin, Saluggia, Italy) with Bio-Plex Manager™ software (Bio-Rad Laboratories Inc., Hercules, California, United USA). Forty-four markers were measured in the samples using two separate Eve Technologies’ panels, as per the manufacturer’s instructions for use: Mouse Cytokine/Chemokine 32-Plex Discovery Assay® Array (MD32) (MILLIPLEX® Mouse Cytokine/Chemokine Magnetic Bead Panel Cat. #MCYTOMAG-70K, MilliporeSigma, Burlington, Massachusetts, USA) and Mouse Cytokine/Chemokine 12-Plex Discovery Assay® Array (MD12) (MILLIPLEX® Mouse Cytokine/Chemokine Magnetic Bead Panel II Cat. # MECY2MAG-73K, MilliporeSigma, Burlington, Massachusetts, USA). Assay sensitivities of these markers range from 0.3–30.6 pg/mL. Individual analyte sensitivity values are available in the MilliporeSigma MILLIPLEX® protocols. Neutrophil chemotaxis Neutrophil chemotactic capacity was measured by quantifying the number of bone marrow neutrophils that migrated across a 75 mm Corning Transwell® membrane (VWR, 29442-118) with 5.0 µm pores, as described44. Neutrophils were sorted from the bone marrow with a neutrophil isolation kit (Miltenyi Biotec), and neutrophil sort purity was evaluated by co-expression of Ly6G and CD11b by flow cytometry44–48. DMEM F/12 + 0.5% BSA medium (650 µL) containing 0% conditioned media, 10% conditioned media, 25% conditioned media, or 50% conditioned media was added to the lower chambers of a transwell plate. Neutrophil suspensions (2 × 106/mL) were added to the transwell with a porous membrane and incubated at 37 °C, 5% CO2 for 3 h. An input well was created by adding 100 µL containing 2 × 105 cells to 550 µL of DMEM F/12 (GIBCO®) with 0.5% BSA (Miltenyi Biotec). After 2 h incubation, cells that had crossed the transwell membrane were collected from the bottom well and counted via flow cytometry by recording events for 30 seconds. Transmigrated cells were represented as a percentage of input wells. Hyaluronan isolation, sizing, and analysis Hyaluronan was isolated as described49,50, with slight modifications. For cultured fibroblast media, hyaluronan (HA) was isolated from conditioned media of treated fibroblasts. Proteins were digested using 1× proteinase K (Invitrogen, 25530015) at 60 °C for 4 h and first precipitation was done with 200 proof ethanol at -20 °C (Day 1). Samples are then washed with 75% ethanol, resuspended in 100 mM ammonium acetate (Sigma Aldrich, A1542) and nucleic acids were digested with Benzonase (EMD Millipore, 70664-3 25 U/µl) at 37 °C (Day 2). Second precipitation was done with 200 proof ethanol and samples were washed with 75% ethanol. Samples were air-dried, resuspended in 100 mM ammonium acetate (Sigma Aldrich, A1542) and incubated at 4 °C (Day 3). Samples were lyophilized and resuspended in 10 M formamide (Sigma Aldrich, F9037) and incubated at 4 °C (Day 4). A 1% agarose gel was made with 1× TAE was used to size HA. After casting, gel was pre-run in 1× TAE for 6 h at 80 V to remove impurities. Loading buffer containing 0.2% bromophenol blue (Sigma Aldrich, B0126, in 10 M formamide) was added to each sample. Samples were run on gel in 1× TAE at 100 V for 2.5–3.0 h and equilibrated in 30% ethanol for 1 h before being stained with 1 mL of 400´ stock stains-all solution [12.5 mg of stains-all (Sigma Aldrich, E9379) to 5 mL of 200 proof ethanol] in 400 mL of 30% ethanol in the dark, overnight (Day 5). Gels were equilibrated in dd-water for 1 h in the dark and destained under ambient light on the bench for 15–20 min. Color images were taken on an EPSON flatbed scanner for presentation purposes. Images for quantitation were taken using a Bio-Rad ChemiDoc using the Stain-Free setting. Stain-Free images were analyzed using Fiji Image J. Lipid mediator quantification by targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) To quantify lipid mediators, 6 mL of culture media collected from 6 × 105 cardiac fibroblast was immediately frozen following IL-1β treatment and stored at -80 °C. Before performing solid phase extraction, samples were thawed and concentrated to 300 µL under a steady stream of N2 gas at 37 °C using a Turbovap (Biotage, Uppsala, Sweden) and stored at -80 °C following the addition of 600 µl of HPLC-grade MeOH. On the day of extraction, 100 µL of HPLC-grade MeOH containing 500 pg of deuterium-labeled internal standards (i.e. Resolvin D2-d5, Resolvin D3-d5, Maresin 1-d5, Maresin 2-d5, Lipoxin A4-d5, Resolvin E1-d4, 5(S)-HETE-d8, 15(S)-HETE-d8, ( + )11(12)-EET-d11, 15-deoxy-Δ12,14-Prostaglandin J2-d4, Prostaglandin E2-d4, and Leukotriene B4-d4) were added to calculate extraction efficiency. Protein precipitates were pelleted by centrifuging samples at 6,200 RCF for 10 min at 4 °C and supernatants were transferred into 12 mL borosilicate glass round-bottom tubes and concentrated to 200 µL total volume. Samples were acidified by the addition of pH 3.5 HPLC-grade H2O. Using an Extrahera automated extraction system (Biotage, Uppsala, Sweden), samples were promptly loaded onto Biotage ISOLUTE C18 SPE columns (cat. no. 220-0020-c, Biotage, Uppsala, Sweden), which had been pre-equilibrated with 3 mL of HPLC-grade MeOH and 3 mL HPLC-grade H2O. After samples were loaded, columns were then neutralized with 5 mL of HPLC-grade H2O and subsequently treated with 5 mL of HPLC-grade hexane to remove neutral lipids. Lipid mediators of interest were then eluted and collected by the addition of 5 mL HPLC-grade methyl formate. Samples were dried to completion with a gentle stream of N2 gas using a Biotage TurboVap Classic and immediately resuspended in 50 μL of HPLC-grade MeOH:H2O (50:50 v/v). LC-MS/MS analysis was carried out on samples using a Kinetex Polar C18 HPLC column (100 mm length x 3 mm diameter; 2.6 μm particle size; 100 Å pore size) (cat. no. 00D-4759-Y0, Phenomenex, Torrance, CA, USA) maintained at 59.0 °C using a Shimadzu LC-20AD with a SIL-20AC autoinjector (Shimadzu, Kyoto, JP), coupled to a 5500 Qtrap (Sciex, Toronto, ON, Canada) as described before51. Targeted LC-MS/MS analysis was carried out first by gradient elution of lipid mediators with a constant 0.5 mL/min mobile phase delivery, initially consisting of 45:55:0.01 (v/v/v) methanol:water:acetic acid, which was then ramped up to 80:20:0.01 over 16.5 min, and then to 98:2:0.01 over the next 2 min. The 5500 Qtrap was operated in negative polarity mode. All data were acquired using Analyst v1.7.1 and analyzed with Sciex OS-Q v3.0.0.3339 software (Sciex). Each analyte was identified using multiple reaction monitoring (MRM) and enhanced product ion (EPI) scans. Chromatographic peaks were quantified if the following criteria were met: (1) RT was within ± 0.1 min of the synthetic standard’s RT; (2) chromatographic peak was composed of at least 5 points across baseline; (3) MS/MS spectra at the appropriate RT contained at least 6 diagnostic ions; (4) signal-to-noise ratio (SNR) was greater than 5; (5) the calculated analyte concentration was greater than the empirically-determined LLOD and LLOQ for the respective analyte. Sciex OS-Q Autopeak Integration Algorithm was used to integrate peaks and to generate peak area and SNR values. Determination of the lower limit of detection (LLOD) and lower limit of quantitation (LLOQ) was carried out as recommended by the International Council for Harmonization analytical guideline Q2 (R2) (https://www.ich.org/page/quality-guidelines). Briefly, for all analytes, calibration standards (Cayman Chemical Company, Ann Arbor, MI, USA) were prepared by mixing twelve synthetic standards with a beginning concentration of 100 pg/μl (Standard 1) and serially diluted in HPLC-grade methanol (Sigma-Aldrich) by 1:2 dilution to a final concentration of 0.048 pg/μl (Standard 12). For each standard, an injection volume of 5 μl was used. At least 5 independent injections of each standard were used to generate data to determine LLOD and LLOQ for each analyte. From the accumulated data, the slope (S) of the calibration curve and the standard deviation (σ) of the y-intercept, which represents the blank condition, were calculated. LLOD and LLOQ were calculated using 3.3*σ/S and 10*σ/S, respectively. An MS/MS spectra matching library was generated using Sciex OS LibraryView v1.4 (Sciex). To generate this library, 5 μl of synthetic standards at concentrations of 100 pg/μl, 6.25 pg/μl and 0.195 pg/μl were injected to create a range of concentration-based MS/MS reference spectra that were added to the LibraryView database. This lipid spectra library was selected as part of the Sciex OS Process Method Library Search function. The search utilized the Smart Confirmation Search and Fit sorting options. The algorithm parameters Precursor Mass Tolerance and fragment Mass Tolerance were both set to ± 0.7 Da. The Use Polarity Intensity Threshold option was set to 0.03. For each chromatographic peak quantified, a library matching score was generated and used to confirm the proper identification of the analyte based on reference MS/MS spectra (Supplementary Fig. 9–13). To determine pg of analyte in each sample, first, a 12-point calibration curve was created for each analyte in the standard mix by using a ratiometric method. With this method, a fixed (500) pg amount of internal deuterated standard (IS) was mixed with decreasing amounts of each synthetic standard, namely 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98, 0.49, or 0.24 pg. The ratio of the peak areas was calculated and used as the Y-axis value, while the ratio of known pg of IS to synthetic standard on each calibration curve sample was used as the X-axis value to generate a calibration curve. All biological samples were spiked with the same pg of deuterated internal standards before extraction, and the peak area ratios of IS and analytes were calculated, and subsequently fitted into the calibration curve using a weighted (1/x) linear regression method to obtain pg of analyte in the biological sample. Each pg of analyte value was normalized to volume of starting cell culture media. Subsequently, each analyte was then normalized to total cell protein and data were analyzed using MetaboAnalyst. In cases where <50% samples reported values, then all three samples were reported as not detected. In cases where >50% had detected values, input of 1/2 of the minimal value detected for that sample group was used. Data underwent log transformation and auto scaling. Bulk RNA sequencing and analysis Total RNA was isolated from murine cardiac fibroblast using the Qiagen RNeasy Micro Kit (74004). RNA quality was evaluated using NanoDrop ONEC (Thermo Scientific), and 100 ng of RNA was sent to sequencing technology center for poly-A RNA sequencing. The TruSeq Stranded mRNA Library Prep Kit (Illumina Cat# 20020594) and TruSeq RNA CD Index Plate (Illumina Cat# 20019792) were used to generate a sequencing library. Size, purity, and semi-quantitation were performed on an Agilent Bioanalyzer 2100 system using the Agilent DNA HS Kit. Single-end sequencing was performed on an Illumina NextSeq 2000, using a P3 100 cycle cartridge with a P3 flow cell. Libraries were sequenced with a single 101 cycle read length with 2 index reads of 8 bp each. FASTQ files were generated utilizing BaseSpace DRAGEN analysis Version 1.2.1. Quality control (QC) of the raw sequence data was performed using FastQC (version 0.10.0) for each sequencing sample52. The sequences were aligned to the mm10 mouse reference genome using STAR version 2.6.53 Differential expression of ENSEMBL protein-coding transcripts was performed using DESeq254, and raw counts were obtained from the STAR-aligned bam format files using HTSeq version 0.10.055. The raw counts were normalized using the Relative Log Expression (RLE) method and then filtered to exclude genes with fewer than ten counts across the samples. DESeq2 guidelines were used to identify differentially expressed genes, and all P values were adjusted for testing multiple genes (Benjamini–Hochberg procedure; p ≤ 0.05). snRNA-Seq analysis of MI hearts We utilized the GEO dataset GSE308914 generated by our group12. A batch-corrected, pre-integrated Seurat object generated in this study was loaded in R version 4.3.3, and subclustering analysis was performed using Seurat version 5.2.1 for fibroblast-enriched clusters (clusters 1, 4, 14, and 18), as previously defined12. The SCT assay was set as the default, and principal component analysis (50 PCs) was performed, followed by inspection of variance using an elbow plot to select dimensions for downstream analysis. Unsupervised subclustering using the Louvain algorithm (20 dimensions, resolution 0.1) identified five fibroblast subclusters, which were annotated using gene signatures obtained from the FindAllMarkers function (min.pct = 0.25, logfc.threshold = 0.25, Wilcoxon test with Bonferroni correction) and known cardiac marker genes from the literature. Differential gene expression analysis was performed using Seurat’s FindMarkers function (Wilcoxon rank-sum test with Bonferroni correction) on cluster-specific comparisons across post–myocardial infarction time points (days 1, 4, 7, and 28) relative to baseline (day 0), analyzed separately for female and male samples. Pathway-specific gene sets for NFκB, JNK, and p38 MAPK signaling were obtained from the MSigDB v2025.1.Mm database using the msigdbr R package (Mus musculus gene symbols). For each pathway, gene lists were generated by integrating multiple expert-curated MSigDB sources, including KEGG, Reactome, BioCarta, the Pathway Interaction Database, and regulatory target gene sets. Differential gene expression data for each curated gene list were extracted from the Seurat analysis, and genes were classified as significantly upregulated or downregulated at each time point using thresholds of log2FC > 0 and FDR < 0.05 (upregulated) or log2FC < 0 and FDR < 0.05 (downregulated). Pathway activity patterns were visualized using barplots generated in R version 4.3.3. Statistical analysis All statistical comparisons were defined a priori based on experimental design and biological hypotheses. For in vivo studies, primary comparisons were performed between fbTAK1⁺ and fbTAK1⁻ mice within each sex. Cross-sex comparisons were not powered and were therefore not emphasized. For in vitro experiments, comparisons were restricted to ligand-treated versus control conditions within genotype. Normality was assessed via Shapiro-Wilk test, where appropriate. Statistical analyses were performed using log-rank Mantel Cox test, parametric unpaired student’s t-test, non-parametric Mann-Whitney U test, ordinary one-way ANOVA with Dunnett post-hoc test, or two-way ANOVA with Šidák’s post-hoc test, as appropriate; all statistical tests were two-sided, unless noted otherwise. Kaplan-Meier analysis was used for analysis of survival, and we excluded mice that expired within the first day after MI, which is consistent with published guidelines21. All statistical analyses were performed using GraphPad Prism, version 10 (GraphPad Software, La Jolla, California). Quantitative data are presented as mean ± SEM, unless otherwise indicated. For summary tables in the Data Supplement, data are reported as mean ± SD. The number of biological replicates (n) is specified in the figure legends or tables for each experiment. The null hypothesis was rejected when p < 0.05. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supplementary Information Reporting Summary Transparent Peer Review file Supplementary Information Reporting Summary Transparent Peer Review file Source data Source Data Source Data